» Articles » PMID: 34993885

Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors

Overview
Journal Endocr Pathol
Specialties Endocrinology
Pathology
Date 2022 Jan 7
PMID 34993885
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Neoplastic cells acquire the ability to proliferate endlessly by maintaining telomeres via telomerase, or alternative lengthening of telomeres (ALT). The role of telomere maintenance in pituitary neuroendocrine tumors (PitNETs) has yet to be thoroughly investigated. We analyzed surgical samples of 24 adult recurrent PitNETs (including onset and relapses for 14 of them) and 12 pediatric primary PitNETs. The presence of ALT was assessed using telomere-specific fluorescence in situ hybridization, methylation of telomerase reverse transcriptase promoter (TERTp) by methylation-specific PCR, and ATRX expression by immunohistochemistry. Among the adult recurrent PitNETs, we identified 3/24 (12.5%) ALT-positive cases. ALT was present from the onset and maintained in subsequent relapses, suggesting that this mechanism occurs early in tumorigenesis and is stable during progression. ATRX loss was only seen in one ALT-positive case. Noteworthy, ALT was observed in 3 out of 5 aggressive PitNETs, including two aggressive corticotroph tumors, eventually leading to patient's death. ALT-negative tumors (87.5%) were classified according to their low (29.2%), medium (50%), and high (8.3%) telomere fluorescence intensity, with no significant differences emerging in their molecular, clinical, or pathological characteristics. TERTp methylation was found in 6/24 cases (25%), with a total concordance in methylation status between onset and recurrences, suggesting that this mechanism remains stable throughout disease progression. TERTp methylation did not influence telomere length. In the pediatric cohort of PitNETs, TERTp methylation was also observed in 4/12 cases (33.3%), but no case of ALT activation was observed. In conclusion, ALT is triggered at onset and maintained during tumor progression in a subset of adult PitNETs, suggesting that it could be used for clinical purposes, as a potential predictor of aggressive behavior.

Citing Articles

DNA Methylation in Pituitary Adenomas: A Scoping Review.

Moller M, Nortvig M, Andersen M, Poulsen F Int J Mol Sci. 2025; 26(2).

PMID: 39859246 PMC: 11765255. DOI: 10.3390/ijms26020531.


A First-in-Class High-Throughput Screen to Discover Modulators of the Alternative Lengthening of Telomeres (ALT) Pathway.

Froney M, Cook C, Cadiz A, Flinter K, Ledeboer S, Chan B ACS Pharmacol Transl Sci. 2024; 7(9):2799-2819.

PMID: 39296266 PMC: 11406699. DOI: 10.1021/acsptsci.4c00251.


Transcriptomic Profiles of Normal Pituitary Cells and Pituitary Neuroendocrine Tumor Cells.

Oh J, Osorio R, Jung J, Carrete L, Choudhary N, Lad M Cancers (Basel). 2023; 15(1).

PMID: 36612109 PMC: 9817686. DOI: 10.3390/cancers15010110.


Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art.

Feola T, Carbonara F, Verrico M, Di Crescenzo R, Gianno F, Colonnese C Cancers (Basel). 2022; 14(17).

PMID: 36077631 PMC: 9454884. DOI: 10.3390/cancers14174093.

References
1.
Asa S, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S . From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer. 2017; 24(4):C5-C8. DOI: 10.1530/ERC-17-0004. View

2.
Trouillas J, Jaffrain-Rea M, Vasiljevic A, Raverot G, Roncaroli F, Villa C . How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers (Basel). 2020; 12(2). PMC: 7072139. DOI: 10.3390/cancers12020514. View

3.
Davis F, Kupelian V, Freels S, McCarthy B, Surawicz T . Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol. 2001; 3(3):152-8. PMC: 1920611. DOI: 10.1093/neuonc/3.3.152. View

4.
Daly A, Rixhon M, Adam C, Dempegioti A, Tichomirowa M, Beckers A . High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006; 91(12):4769-75. DOI: 10.1210/jc.2006-1668. View

5.
Perry A, Graffeo C, Marcellino C, Pollock B, Wetjen N, Meyer F . Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm. J Neurol Surg B Skull Base. 2018; 79(1):91-114. PMC: 5796823. DOI: 10.1055/s-0038-1625984. View